MAM
NGM

Meeder Asset Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Meeder Asset Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-803
Closed -$9K – 2567
2020
Q1 		$9K Buy
803
+775
+2,768% +$12.7K ﹤0.01% 1589
2019
Q4 		$1K Buy
+28
New +$409 ﹤0.01% 2187

Other funds holding NGM

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JRP
Jasper Ridge Partners Menlo Park, California $4.49B AUM 18.72% 1-Year Est. Return

Meeder Asset Management's NGM Position: Q2 2020 in Review

Meeder Asset Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2020, closing a stake of 803 shares — an estimated $9K sold.

Meeder Asset Management first reported a position in NGM in Q4 2019 and held it in 2 quarters. The position peaked at $9K in Q1 2020. 84 funds tracked by Wall St. Rank hold NGM as of Q2 2020.

  • Meeder Asset Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 803 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $9K.
  • Meeder Asset Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Meeder Asset Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $9K in Q1 2020.
  • 84 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.